CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase. A webcast of the presentation can be found under the IR Events tab of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals H ...

Alliant Energy (LNT) Q1 2025 Earnings Call May 09, 2025 10:00 AM ET Company Participants Susan Gille - Manager of Investor RelationsLisa Barton - Director, President & CEORobert Durian - EVP and CFOJames Schaefer - Senior Managing DirectorNicholas Campanella - DirectorPaul Fremont - Managing DirectorAndrew Weisel - DirectorPaul Zimbardo - Managing Director Conference Call Participants Rinny S - Equity Research Analyst Operator Thank you for holding, and welcome to Alliant Energy Energy's First Quarter twent ...

Q1 2025 Earnings Review May 9, 2025 Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Statements made in this presentation for TXNM Energy, Inc. ("TXNM"), Public Service Company of New Mexico ("PNM"), or Texas-New Mexico Power Company ("TNMP") (collectively, the "Company") that relate to future events or expectations, projections, estimates, intentions, goals, targets, and strategies, including the unaudited financial results and earnings guidance, are ma ...

LeMaitre Vascular (LMAT) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Dorian LeBlanc - CFOGeorge LeMaitre - Chairman & CEOShaymus Contorno - Equity Research AssociateDavid Roberts - President & DirectorMichael Petusky - Managing DirectorRick Wise - Managing Director - Medical Technology & SuppliesDaniel Stauder - Director - Equity Research Conference Call Participants Michael Sarcone - AnalystFrank Takkinen - Senior Research AnalystJim Sidoti - AnalystBrett Fishbin - Vice President & ...

Financial Data and Key Metrics Changes - Earnings per share (EPS) for Q1 2025 were $1.05, an increase of nearly 11% compared to $0.95 in Q1 2024, affirming the company's full-year EPS guidance of 8% growth [7][12] - Consolidated reported earnings were $1.50 per share, up $0.10 per share versus the same period in 2024, with revenues higher by $0.44 per share due to authorized rate increases and acquisitions [13][14] - Operating costs increased by $0.15 per share, primarily due to employee-related costs and acquisition-related expenses [14] Business Line Data and Key Metrics Changes - The company achieved a constructive settlement in the general rate case in Missouri, with an annualized revenue increase of $63 million expected [15] - In Virginia, a settlement approved a $15 million annualized increase in water and wastewater revenues [15] Market Data and Key Metrics Changes - The company continues to expect to grow its dividend at 7% to 9% per year, in line with its EPS growth target [11] - The total debt to capital ratio was 58%, within the target of less than 60%, with strong credit ratings affirmed by S&P and Moody's [21] Company Strategy and Development Direction - The company aims for long-term earnings and dividend growth of 7% to 9%, driven by a capital investment program targeting approximately $3.3 billion in 2025 [10][22] - The company is focused on infrastructure investments, particularly in PFAS remediation and lead service line replacement, while maintaining a strong regulatory and operational execution [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute financial and operational plans, with no expected material impact from recent tariff-related announcements [20] - The company highlighted the need for significant investments in U.S. water infrastructure, estimating a total of $625 billion over the next twenty years [29] Other Important Information - The Board approved an increase in the quarterly cash dividend from $0.765 to $0.825 per share, marking an 8.2% increase [11] - The company is well-positioned for growth through acquisitions, with approximately 37,000 customer connections under agreement [26] Q&A Session Summary Question: Thoughts on pulling forward 2026 equity issuance - Management stated there are no plans to pull forward equity issuance and will evaluate the market as needed [37] Question: Acquisition outlook under potential recession - Management expects a continuous flow of acquisition opportunities, potentially driven by recession or reduced federal funding [38] Question: Update on California rate case - Management did not disclose the percentage increase for the California rate case and confirmed a separate proceeding for cost of capital [43][44] Question: Update on California desalination project - Management confirmed that the last major permit approval was received, and they expect to break ground on the desalination project this year [49] Question: Legislative progress and opportunities - Management did not quantify the opportunities from legislative changes but noted they would help earned returns in each state [56]

American Water Works Company (AWK) Q1 2025 Earnings Call May 01, 2025 09:00 AM ET Company Participants Aaron Musgrave - Vice President of Investor RelationsJohn Griffith - PresidentDavid Bowler - Executive VP & CFOCheryl Norton - Executive VP & COOM. Susan Hardwick - CEOAnthony Crowdell - Managing DirectorPaul Zimbardo - Managing Director Conference Call Participants Richard Sunderland - AnalystGregg Orrill - Analyst Operator Good morning, and welcome to American Water's First Quarter twenty twenty five Ear ...

Third Quarter 2020 Financial Results and Business Update Conference Call October 29, 2020 Third Quarter 2020 Financial Results Conference Call AGENDA • Introduction 2 • Peggy Pinkston, VP, Investor Relations • CEO Opening Remarks • Clay Siegall, Ph.D. – President & Chief Executive Officer • Commercial Update • Chip Romp – EVP, Commercial U.S. • Financial Results and Guidance • Todd Simpson – Chief Financial Officer • R&D Highlights • Roger Dansey, M.D. – Chief Medical Officer • Q&A Forward-Looking Statement ...